1 comment by Mikail
Thank you for this great overview of chemogenetics. As you have referred to in the article there is enormous potential in the clinical use of DREADDs and other chemogenetic technologies. I would like to draw your attention to our recently published work showing that the neuroleptic drug olanzapine is a potent DREADD activator (DOI: 10.1126/sciadv.aaw1567). Since it is already clinically approved this combination is currently the most promising for treating diseases such as epilepsy. We further discuss the principal designer receptor technologies for epilepsy in a review published this month (DOI: 10.1016/j.ebiom.2019.04.059).